Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| First Tracks Biotherapeutics, Inc.TRAX · Entity 4696 | Chief Business Officer | August 15, 2026 | August 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
First Tracks Biotherapeutics, Inc.
Report date August 15, 2026 · Filed August 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Performance Stock UnitsSEC Table II · derivative / convertible security | Direct | 137,651 |
Reported balance
After 2026-08-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-08-15 · Grant · Acquired 60,492 · Balance 137,651 F1: Represents performance-based restricted stock units ("PSUs") that were earned by the Reporting Person upon the achievement of certain performance criteria as certified by the Compensation Committee of the Issuer's Board of Directors on August 15, 2026. F2: Each PSU represents a conditional right to receive one share of the Issuer's Common Stock. F3: The PSUs vest and settle over two years; 50% vests on August 15, 2027 and 50% vests on July 1, 2028, subject to the continuing service of the Reporting Person on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents performance-based restricted stock units ("PSUs") that were earned by the Reporting Person upon the achievement of certain performance criteria as certified by the Compensation Committee of the Issuer's Board of Directors on August 15, 2026.
F2: Each PSU represents a conditional right to receive one share of the Issuer's Common Stock.
F3: The PSUs vest and settle over two years; 50% vests on August 15, 2027 and 50% vests on July 1, 2028, subject to the continuing service of the Reporting Person on each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 15, 2026 Filed Aug 18, 2026 20:05 UTC | First Tracks Biotherapeutics, Inc. TRAX · Entity 4696 | GrantPerformance Stock Units · Derivative | 60,492 | $0.00 | $0.00 |
DisclosureSEC source: 0002128786-26-000006 · form4-08182026_040807.xml · derivative · entry 1 STONE BENJAMIN · CIK 0002128786 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 137,651 Underlying: Common Stock · 60,492 shares Expires not disclosed F1 · security: Represents performance-based restricted stock units ("PSUs") that were earned by the Reporting Person upon the achievement of certain performance criteria as certified by the Compensation Committee of the Issuer's Board of Directors on August 15, 2026. F2 · derivative.exercise_price: Each PSU represents a conditional right to receive one share of the Issuer's Common Stock. F3 · derivative.exercise_date: The PSUs vest and settle over two years; 50% vests on August 15, 2027 and 50% vests on July 1, 2028, subject to the continuing service of the Reporting Person on each vesting date. F3 · derivative.expiration_date: The PSUs vest and settle over two years; 50% vests on August 15, 2027 and 50% vests on July 1, 2028, subject to the continuing service of the Reporting Person on each vesting date. Read SEC document |
| August 02, 2026 Filed Aug 5, 2026 22:26 UTC | First Tracks Biotherapeutics, Inc. TRAX · Entity 4696 | GrantPerformance Stock Units · Derivative | 60,492 | $0.00 | $0.00 |
DisclosureSEC source: 0002128786-26-000004 · form4-08052026_100823.xml · derivative · entry 1 STONE BENJAMIN · CIK 0002128786 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,159 Underlying: Common Stock · 60,492 shares Expires not disclosed F1 · security: Represents performance-based restricted stock units ("PSUs") that were earned by the Reporting Person upon the achievement of certain performance criteria as certified by the Compensation Committee of the Issuer's Board of Directors on August 2, 2026. F2 · derivative.exercise_price: Each PSU represents a conditional right to receive one share of the Issuer's Common Stock. F3 · derivative.exercise_date: The PSUs vest and settle over two years; 50% vests on August 2, 2027 and 50% vests on July 1, 2028, subject to the continuing service of the Reporting Person on each vesting date. F3 · derivative.expiration_date: The PSUs vest and settle over two years; 50% vests on August 2, 2027 and 50% vests on July 1, 2028, subject to the continuing service of the Reporting Person on each vesting date. Read SEC document |
| May 12, 2026 Filed May 14, 2026 20:05 UTC | First Tracks Biotherapeutics, Inc. TRAX · Entity 4696 | GrantEmployee Stock Option (right to buy) · Derivative | 72,300 | $0.00 Strike: $17.81 | $0.00 |
DisclosureSEC source: 0002128786-26-000003 · form4-05142026_040505.xml · derivative · entry 2 STONE BENJAMIN · CIK 0002128786 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,300 Underlying: Common Stock · 72,300 shares Expires 2036-05-11 F3 · derivative.exercise_date: The stock option vests as to 25% of the total shares on May 12, 2027, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F4 · balance_after: In addition to the options to purchase a total of 72,300 shares of common stock as set forth in Table II, the Reporting Person also holds additional options to purchase up to an aggregate of 337,140 shares of common stock, which options vest according to their terms. Read SEC document |
| May 12, 2026 Filed May 14, 2026 20:05 UTC | First Tracks Biotherapeutics, Inc. TRAX · Entity 4696 | GrantRestricted Stock Unit · Derivative | 26,700 | $0.00 | $0.00 |
DisclosureSEC source: 0002128786-26-000003 · form4-05142026_040505.xml · derivative · entry 1 STONE BENJAMIN · CIK 0002128786 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,700 Underlying: Common Stock · 26,700 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F2 · derivative.exercise_date: The RSUs vests as to 25% of the total RSUs annually commencing on May 12, 2027 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F2 · derivative.expiration_date: The RSUs vests as to 25% of the total RSUs annually commencing on May 12, 2027 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.